Arthneeti
Latest: Nureca Q2 FY27 results →All Q4 FY26 results →
N

Nureca

Q4 FY26

Nureca Q4 FY26 investor presentation: Revenue & Margins

Q4 FY26 investor presentation: what the company reported on revenue, margins and capex.

Price₹321
Market cap₹306 Cr
P/E70.5
Updated16 Oct 2026
Read4 min read

Nureca Q4 FY26 key numbers

Revenue
Customer base: 1.86 crore happy families; 290% revenue contribution from online sales.

As stated in Nureca's Q4 FY26 investor presentation · published 16 Oct 2026. Reported figures, not investment advice.

Based on Nureca's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

The short version

Q4 FY26 Gross Merchandise Value (GMV): INR 49.7 Crore, 4% YoY growth (Q4 FY25: INR 48 Crore) - Q4 FY26 Revenue from Operations: INR 35.4 Crore, 12% YoY growth (Q4 FY25: INR 31.7 Crore) - FY26 Revenue Q4 FY26 EBITDA / Operating Profit: INR 2.5 Cr; Operating Margin 7.2%, representing a 113% YoY growth from INR 1.2 Cr and 3.8% margin in Q4 FY25 (Page 6). - Q4 FY26 Profit After Tax (PAT): INR -6.1 Cr, a decline of 347% YoY from INR 2.5 Cr and 7% margin in Q4 FY25; the negative PAT is attributed to losses from investments disclosed under "Fair value changes and net loss on investment" as per IND AS compliance (Page 6).

From Nureca's Q4 FY26 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

  • Q4 FY26 Gross Merchandise Value (GMV): INR 49.7 Crore, 4% YoY growth (Q4 FY25: INR 48 Crore)
  • Q4 FY26 Revenue from Operations: INR 35.4 Crore, 12% YoY growth (Q4 FY25: INR 31.7 Crore)
  • FY26 Revenue from Operations: INR 146.96 Crore, 34% YoY increase from previous year
  • Customer base: 1.86 crore happy families; 290% revenue contribution from online sales
  • Over 2 million users of the Dr Trust 360 mobile app

2 more points from Nureca's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Nureca said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

- Fixed Assets increased by ₹6 Crore for land purchased during FY26 (Page 22). - Wholly owned manufacturing subsidiary Nureca Technologies Pvt Ltd (NTPL) started operations in April 2022 (Page 15). - NTPL is USFDA registered (No: 3036779619) and manufactures multiple product categories including BP monitors, nebulizers, and thermometers (Page 15). - Investment in manufacturing is focused on quality, innovation, safety, and efficiency (Page 9 and Page 15). Summary: Current capex highlighted is ₹6 Cr land purchase in FY26;

Fundraising & Capital Structure

See what Nureca said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Specifically: - The focus is on financial results, key performance indicators, manufacturing, distribution, product portfolio, and growth drivers. All information pertains to revenue, profit, operational metrics, manufacturing capacity, distribution reach, and digital initiatives without reference to order-specific data.

Nureca — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹59 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Nureca Ltd's management said in earlier quarters

Others in Healthcare Equipment & Supplies this season

  • Vaidya Sane Ayurved Laboratories Ltd (Q4 FY26)

    170-180 crores driven by higher patient additions, increased hospital utilization, and franchise clinic growth. Key concall takeaways from Vaidya Sane Ayurved…

  • OSEL Devices Ltd (Q4 FY26)

    PAT growth was 45.7% in FY26; management is optimistic about sustaining or improving profitability and EPS in coming years. Key concall takeaways from OSEL…

  • Vasa Denticity Ltd (Q4 FY26)

    The company has a debt line of ₹15 crore available from financial partners. Key concall takeaways from Vasa Denticity Ltd's Q4 FY26 earnings call — and how it…

  • QMS Medical Allied Services Ltd (Q4 FY26)

    INR 13 crores in FY26 to INR 18-20 crores in FY27. Key concall takeaways from QMS Medical's Q4 FY26 earnings call — and how it ranks against sector peers.

Compare:vs Poly Medicure Ltdvs Molbio Diagnostivs Sahajanand Medical Technologies Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Nureca and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Nureca Q4 FY26 results?

Q4 FY26 Gross Merchandise Value (GMV): INR 49.7 Crore, 4% YoY growth (Q4 FY25: INR 48 Crore) - Q4 FY26 Revenue from Operations: INR 35.4 Crore, 12% YoY growth (Q4 FY25: INR 31.7 Crore) - FY26 Revenue Q4 FY26 EBITDA / Operating Profit: INR 2.5 Cr; Operating Margin 7.2%, representing a 113% YoY growth from INR 1.2 Cr and 3.8% margin in Q4 FY25 (Page 6). - Q4 FY26 Profit After Tax (PAT): INR -6.1 Cr, a decline of 347% YoY from INR 2.5 Cr and 7% margin in Q4 FY25; the negative PAT is attributed to losses from investments disclosed under "Fair value changes and net loss on investment" as per IND AS compliance (Page 6).

What is Nureca share price analysis?

Nureca currently shows a neutral. The stock trades at a P/E of 70.5 with a market cap of ₹306 Cr. Investors should review the full earnings analysis for detailed insights.

Is Nureca planning capital expenditure?

Fixed Assets increased by ₹6 Crore for land purchased during FY26 (Page 22).

Keep Nureca on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.